|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Amylin Pharmaceuticals, Inc. Eli Lilly and Company |
| Information provided by: | Amylin Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT00044668 |
Purpose
This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.
| Condition | Intervention | Phase |
|
Diabetes Mellitus, Type 2 |
Drug: AC2993 (synthetic exendin-4) |
Phase III |
| MedlinePlus related topics: | Diabetes |
| ChemIDplus related topics: | Exenatide Metformin Metformin hydrochloride Dextrose |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination |
| Estimated Enrollment: | 150 |
| Study Start Date: | August 2002 |
Eligibility
| Ages Eligible for Study: | 20 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Hungary | |||||
| Peterfy Teaching Hospital | |||||
| Budapest, Hungary, H 1076 | |||||
| Diagnostic Units Hungary Kft. | |||||
| Budapest, Hungary, H 1036 | |||||
| Uzsoki Street Municipal Hospital | |||||
| Budapest, Hungary, H 1145 | |||||
| Amylin Pharmaceuticals, Inc. |
| Eli Lilly and Company |
| Study Director: | Lisa Porter, MD | Amylin Pharmaceuticals, Inc. |
More Information
Link to study results on ClinicalStudyResults.org 
  |
| Study ID Numbers: | 2993-117 |
| First Received: | September 3, 2002 |
| Last Updated: | November 5, 2007 |
| ClinicalTrials.gov Identifier: | NCT00044668 |
| Health Authority: | United States: Food and Drug Administration; Hungary: National Institute of Pharmacy |
|
|
|
|